CYTOMED THERAPEUTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.067 USD | +2.34% |
|
+1.33% | -57.81% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Capitalization 1 | 56.49 | 23.86 | - |
| Enterprise Value (EV) 1 | 50.22 | 19.5 | 21.53 |
| P/E ratio | -17.1 x | -10.3 x | -10.3 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | 45.9 x | 45.9 x |
| EV / Revenue | - | 37.5 x | 41.4 x |
| EV / EBITDA | - | - | - |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 11,529 | 11,540 | - |
| Reference price 2 | 4.900 | 2.067 | 2.067 |
| Announcement Date | 4/22/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | - | 0.52 | 0.52 |
| EBITDA | - | - | - | - |
| EBIT 1 | - | - | -1.846 | -1.846 |
| Operating Margin | - | - | -355% | -355% |
| Earnings before Tax (EBT) 1 | - | -3.032 | -1.942 | -1.942 |
| Net income 1 | -2.344 | -3.033 | -1.942 | -1.942 |
| Net margin | - | - | -373.46% | -373.46% |
| EPS 2 | -0.2994 | -0.2862 | -0.2000 | -0.2000 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 5/1/23 | 4/22/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -0.462 | -0.462 | -0.462 | -0.462 | -0.462 |
| Operating Margin | - | -355.38% | -355.38% | -355.38% | -355.38% | -355.38% |
| Earnings before Tax (EBT) 1 | - | -0.486 | -0.486 | -0.486 | -0.486 | -0.486 |
| Net income 1 | -1.605 | -0.486 | -0.486 | -0.486 | -0.486 | -0.486 |
| Net margin | - | -373.85% | -373.85% | -373.85% | -373.85% | -373.85% |
| EPS 2 | -0.1636 | -0.0500 | -0.0500 | -0.0500 | -0.0500 | -0.0500 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/17/23 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 6.27 | 4.36 | 2.33 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 0.04 | 0.38 | 0.4 |
| Capex / Sales | - | - | 73.08% | 76.92% |
| Announcement Date | 5/1/23 | 4/22/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.067
USD
Average target price
5
USD
Spread / Average Target
+141.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -57.81% | 23.86M | |
| +9.83% | 118B | |
| +10.80% | 106B | |
| -10.84% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.11% | 15.97B | |
| +6.62% | 14.03B | |
| +17.53% | 11.67B |
- Stock Market
- Equities
- GDTC Stock
- Financials CytoMed Therapeutics Limited
